Eagle Health Investments LP Has $26.40 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Eagle Health Investments LP boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 627,600 shares of the biopharmaceutical company’s stock after acquiring an additional 65,900 shares during the quarter. Ultragenyx Pharmaceutical accounts for approximately 6.5% of Eagle Health Investments LP’s investment portfolio, making the stock its 7th biggest holding. Eagle Health Investments LP owned 0.68% of Ultragenyx Pharmaceutical worth $26,403,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in RARE. Bamco Inc. NY bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $2,666,000. Principal Financial Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after acquiring an additional 76,150 shares in the last quarter. Cerity Partners LLC purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter worth $1,773,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 294 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd raised its holdings in shares of Ultragenyx Pharmaceutical by 193.1% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,151 shares of the biopharmaceutical company’s stock valued at $1,064,000 after purchasing an additional 12,617 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $37.98 on Thursday. The stock has a market capitalization of $3.51 billion, a price-to-earnings ratio of -5.99 and a beta of 0.67. The company’s fifty day simple moving average is $41.72 and its two-hundred day simple moving average is $47.08. Ultragenyx Pharmaceutical Inc. has a 1 year low of $36.71 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insider Activity

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 14,439 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares of the company’s stock, valued at $4,536,948.60. This trade represents a 11.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Howard Horn sold 1,785 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the transaction, the chief financial officer now directly owns 106,169 shares of the company’s stock, valued at $4,289,227.60. The trade was a 1.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on RARE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Piper Sandler lowered their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday, March 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $91.71.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.